Summary : Pfizer and Ionis Pharmaceuticals announced that the former is abandoning its vupanorsen program…
Pfizer’s XELJANZ® (Tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitis
Abstract: The European Commission has approved Pfizer`s first-of-its-kind oral Janus kinase (JAK) inhibitor XELJANZ® (Tofacitinib)…
Active Pharmaceutical Ingredients (API)Risankizumab
European Commission approves AbbVie’s Skyrizi (Risankizumab) to Treat Adults with Active Psoriatic Arthritis.
KEYPOINTS: AbbVie announces that the European Commission (EC) has approved SKYRIZI (Risankizumab, 150 mg, subcutaneous…